Science

Microsomal prostaglandin E synthase-1 (mPGES-1) is an inducible enzyme downstream of the cyclooxygenase enzymes, is upregulated by inflammatory stimuli and is involved in the inflammatory processes of cardiovascular diseases and cancer.

Use of mPGES-1 inhibitors in microvascular disease:

Our research has revealed novel uses for mPGES-1 inhibitors in the treatment of microvascular disease and represents a unique opportunity for development of new medicines.

Cardiovascular morbidity and mortality are common in chronic inflammatory diseases due to vascular inflammation and endothelial dysfunction.

Selective deletion of mPGES-1 activity can have several beneficial effects on microvascular disease, such as:

  • reduced production of the pro-inflammatory mediator, PGE2
  • increased production of vasoprotective prostacyclin

Collectively, these effects lead to anti-inflammatory, vasodilatory and platelet inhibitory benefit to patients.

Use of mPGES-1 inhibitors in cancer:

Recent research has indicated a role of PGE2 in cancer proliferation and immune evasion. Gesynta is currently evaluating this opportunity in collaboration with leading scientists in the fields.

Products

Gesynta Pharma develops selective mPGES-1 inhibitors for microvascular disease in chronic inflammatory conditions. The first clinical candidate recently completed a clinical phase I study.

Clinical: GS-248, is a highly potent mPGES-1 inhibitor with excellent drug-like properties in clinical development for microvascular disease. The first indication is associated with reduced digital blood flow in systemic sclerosis patients. Such reduced blood flow leads to painful episodes of Raynaud’s phenomenon, and may develop into debilitating digital ulcers. The upcoming Phase IIa study aims to demonstrate beneficial effects of GS-248 in patients with systemic sclerosis. We will study frequency, pain and quality of life of Raynaud’s attacks, digital blood flow and a wide range of inflammation markers.

Pre-clinical: GS-659, GS-073. We recently acquired a late-stage drug discovery project, including several proprietary molecules originating from AstraZeneca. The front runners of this project are currently undergoing testing to identify potent and druggable molecules to be explored for treatment of additional diseases characterized by inflammation, such as cardiovascular diseases and cancer.

Company

Gesynta Pharma was founded on the basis of:

  • access to potent and selective mPGES-1 inhibitors for pharmacological research and clinical development
  • proprietary knowledge of novel aspects of biological/medical effects caused by mPGES-1 inhibition leading to new opportunities in novel indications
  • a team with extensive experience

Gesynta Pharma has been supported by Karolinska Institutet Innovation AB, Novo Nordisk Foundation, Swelife and VINNOVA - Swedish Governmental Agency for Innovation

Team

Founders

Gesynta Pharma is being actively managed by its founders, who contribute extensive experience in the fields of mPGES-1 research, medical, drug development through their work in board and management team

Group photo
Gesynta Pharma founders (Front left to right: Gunilla Ekström, Charlotte Edenius, Urban Paulsson. Back left to right: Ralf Morgenstern, Per-Johan Jakobsson, Patric Stenberg)

Board of Directors

• Co-Founder, LLM
• 20+ years in the life science industry including inhouse counsel at Pharmacia Corporation and general counsel at Vitrolife AB. Focused on transactions involving licensing, acquisitions and divestment.
• Co-founder of Cormorant Pharmaceuticals (acquired by BMS in 2016). Chairman of several pharma companies

• PhD (oncology), University of Cambridge
• Partner at Hadean Ventures, a Stockholm/Oslo based European life science venture fund
• Other positions include board/observer positions at Pipeline Therapeutics, Inc (San Diego, USA), Saga Diagnostics AB (Lund, Sweden) and Abliva AB (Lund, Sweden)

• Co-Founder, MD/PhD
• 25+ years in eicosanoid research and drug development
• 20+ years in pharmaceutical industry incl. leading positions at AZ, Biolipox, Orexo and Medivir
• Experience from all phases of drug development, senior management and strategic business development incl. successful partnering/licensing (e.g. with BI on mPGES inhibitors and J&J on arachidonic acid related targets)

• Co-Founder, MD/PhD
• 25+ years within pharmaceutical industry, incl. leading positions at AZ, Orexo, Karolinska Development and Immuneed
• Extensive experience of drug development, from discovery to clinic development
• CEO of virtual companies, non-executive Director on several pharma companies, eg NovaSAID

• MD/PhD
• Specialist in Cardiology and Internal Medicine
• Formerly Vice President & Head of Cardiovascular & Gastrointestinal Therapy Areas, Global R&D, AZ
• Other board positions include Athera Biotechnology AB, IR Lab AB, Cereno Scientific AB, European Society of Cardiology

• BA in Science and Economy
• 45+ years in the pharmaceutical industry, including Bristol Myers and Nobel Pharma.
• Founder of Orphan Europe Sarl which was sold to the Recordati Group, Italy. Board member of Synphora, Sensidose, Sixera, Prostalund and Premalux

• PhD, MBA
• +10 years of academic research experience at Karolinska institutet & McGill University
• Investment banking & asset valuation experience at Caisse de dépôt et placement du Québec & Foster Rosenblatt in Kanada

• Co-Founder, PhD
• 20 + years in pharmaceutical and ADME research and development, 15 years in industry
• CEO, CSO, BD, staff scientist of pharmaceutical business, research and development efforts from discovery to phase III
• Corporate experience ranging from virtual companies (eg NovaSAID) to major pharma (eg Pfizer)

• Co-Founder, MD/PhD
• 25+ years in eicosanoid research and drug development
• 20+ years in pharmaceutical industry incl. leading positions at AZ, Biolipox, Orexo and Medivir
• Experience from all phases of drug development, senior management and strategic business development incl. successful partnering/licensing (e.g. with BI on mPGES inhibitors and J&J on arachidonic acid related targets)

• Co-Founder, MD/PhD
• 25+ years within pharmaceutical industry, incl. leading positions at AZ, Orexo, Karolinska Development and Immuneed
• Extensive experience of drug development, from discovery to clinic development
• CEO of virtual companies, non-executive Director on several pharma companies, eg NovaSAID

R&D team leaders

Research and Development at Gesynta Pharma is managed by an experienced team of pharmaceutical and medical research and development professionals. The team competency spans all essential aspects of the drug development process.

• Co-Founder, PhD
• 20 + years in pharmaceutical and ADME research and development, 15 years in industry
• CEO, CSO, BD, staff scientist of pharmaceutical business, research and development efforts from discovery to phase III
• Corporate experience ranging from virtual companies (eg NovaSAID) to major pharma (eg Pfizer)

• M.Sc. Organic Chemistry
• 20+ years experience of API manufacture within the pharmaceutical industry
• Involved in projects ranging from early phase development to commercial production
• Earlier positions: Senior Scientist, Process Chemistry and Senior Process Engineer at AstraZeneca, CMC Project Manager at Medivir

• PhD
• Responsible for the nonclinical development, consultant
• 15+ years in pharmaceutical industry e.g. project leader, group manager at AZ and senior consultant in drug development
• Extensive experience of drug development, from discovery to clinical development

• Co-Founder, MD/PhD
• 25+ years in eicosanoid research and drug development
• 20+ years in pharmaceutical industry incl. leading positions at AZ, Biolipox, Orexo and Medivir
• Experience from all phases of drug development, senior management and strategic business development incl. successful partnering/licensing (e.g. with BI on mPGES inhibitors and J&J on arachidonic acid related targets)

• MD/PhD/Associate professor
• The author of > 100 articles and book chapters
• 15+ years in pharmaceutical industry incl. leading positions at AZ, Biolipox and Orexo
• Experience from all phases of drug development

• Co-Founder, Professor
• Dept of Medicine, Karolinska Institutet, specialist in rheumatology and Extensive experience in eicosanoid research.
• The author of > 130 articles• Group leader at KI (ki.se/en/meds/research-group-per-johan-jakobsson-0)
• Discovered and characterized the mPGES-1 in 1998

• Co-Founder, MD/PhD
• 25+ years within pharmaceutical industry, incl. leading positions at AZ, Orexo, Karolinska Development and Immuneed
• Extensive experience of drug development, from discovery to clinic development
• CEO of virtual companies, non-executive Director on several pharma companies, eg NovaSAID

Jobs

    We are currently fully staffed. Future open positions will be announced here.